Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 11/20 | 0.56 |
| ▸ | BCL2 | P10415 | 6/20 | 0.56 |
| ▸ | BCL2L1 | Q07817 | 3/20 | 0.56 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17686330 | 0.93 | MCL1 (0.54) | MCL1BCL2BCL2L1EGLN1LIPG | |
| SCHEMBL17686346 | 0.85 | MCL1 (0.51) | MCL1BCL2BCL2L1EGLN1LIPG | |
| SCHEMBL17686331 | 0.83 | MCL1 (0.53) | MCL1BCL2BCL2L1EGLN1LIPG | |
| SCHEMBL17686338 | 0.79 | MCL1 (0.56) | MCL1BCL2BCL2L1HTR2AHTR2C | |
| SCHEMBL17686345 | 0.78 | MCL1 (0.56) | MCL1BCL2BCL2L1LIPG | |
| SCHEMBL17686289 | 0.74 | MCL1 (0.62) | MCL1BCL2BCL2L1EGLN1LIPG | |
| SCHEMBL17686348 | 0.72 | MCL1 (1.00) | MCL1BCL2BCL2L1 | |
| SCHEMBL17686316 | 0.72 | MCL1 (1.00) | MCL1BCL2BCL2L1 | |
| SCHEMBL17686307 | 0.72 | MCL1 (0.53) | MCL1BCL2BCL2L1HTR2AHTR2C | |
| SCHEMBL17686296 | 0.72 | MCL1 (0.64) | MCL1BCL2BCL2L1EGLN1LIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9949965-B2 | Tricyclic indole Mcl-1 inhibitors and uses thereof | VANDERBILT UNIVERSITY (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160106731-A1 | TRICYCLIC INDOLE MCL-1 INHIBITORS AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160106731-A1 | TRICYCLIC INDOLE MCL-1 INHIBITORS AND USES THEREOF | MCL1, BCL2L1, BCL3 | MCL1 1/4885BCL2 4/4885BCL2L1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.